The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial Article

cited authors

  • Dearnaley, David P.; Saltzstein, Daniel R.; Sylvester, John E.; Karsh, Lawrence; Mehlhaff, Bryan A.; Pieczonka, Christopher; Bailen, James L.; Shi, Hongliang; Ye, Zhan; Faessel, Helene M.; Lin, Huamao; Zhu, Yanyan; Saad, Fred; MacLean, David B.; Shore, Neal D.

authors

Publication Date

  • August 1, 2020

webpage

published in

category

keywords

  • Androgen deprivation therapy
  • Degarelix
  • External beam radiotherapy
  • Gonadotropin-releasing
  • Neoadjuvant/adjuvant
  • Prostate cancer
  • Relugolix
  • TAK-385
  • hormone analogues

start page

  • 184

end page

  • 192

volume

  • 78

issue

  • 2